Zealand Pharma Seeks Partners for Rare-disease Assets as Obesity Focus Grows
Danish biotech Zealand Pharma has resumed talks with potential partners for rare-disease drug glepaglutide as it focuses investment on its obesity pipeline, the company's... Reuters Health Information















